LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in food and environment testing, announces that it has acquired VBM Laboratoriet A/S (“VBM”), one of the leading laboratories for testing for the environment and construction materials sectors in Denmark.
Founded in 1985, VBM has developed into one of the top three environment testing laboratories in the country, with a strong reputation for testing of contaminated soil and building materials particularly within the construction sector. The company employs 80 staff across its 3 sites, and generated revenues in excess of DKK 45m in 2016.
VBM’s primary competencies and customer segments in environment testing strongly complement Eurofins’ capabilities in the local market. The acquisition of VBM should therefore further strengthen, as well as expand the Group’s leadership in the Danish environment testing market. As part of the transaction, current VBM leader Jesper Gamst will remain as managing director of VBM Laboratories.
Comment from Klaus Melsing Bjørnholdt and Jesper Gamst, VBM shareholders: “We are proud to have developed VBM Laboratories to be one of the market leaders in Denmark and we are convinced that the agreement with Eurofins will safeguard further positive development for VBM and its team”.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of VBM demonstrates our commitment to continually reinforce our leadership in markets where we are active. The complementary businesses of VBM and Eurofins also illustrate the Group’s strategy of expanding our leading operational footprint. We look forward to supporting VBM in further developing their market share together with Eurofins, by providing access to the full range of capabilities of the Group.
For more information, please visit www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 27,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.